DGAP-Adhoc
1068
0 Kommentare
Agennix AG Announces Extraordinary General Meeting
1068 
0 KommentareAgennix AG / Key word(s): AGM/EGM
09.04.2013 22:54
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
/
Ad Hoc Announcement
According to Sec. 15 WPHG
For Immediate Release
Agennix AG Announces Extraordinary General Meeting
Munich (Germany) and Princeton, NJ, April 9, 2013 - The Management Board
and Supervisory Board of Agennix AG (Frankfurt Stock Exchange: AGX) today
have approved an agenda for an Extraordinary General Meeting (EGM) to be
held on May 22, 2013, including proposals for the liquidation of Agennix AG
and a 20:1 reverse stock split. The Company continues to pursue various
strategic options and will ask shareholders to vote on these two proposals,
among other items. The liquidation of Agennix AG would eliminate the public
entity but still permit potential transactions involving the Company's
clinical assets and its U.S. subsidiaries as part of the process. The
reverse stock split is proposed to reduce the number of outstanding shares
to address the situation under § 92 par. 1 AktG by covering losses and to
permit issuance of shares in connection with a potential strategic
transaction. Management expects to make a recommendation by the date of the
EGM to approve either the reverse stock split or the liquidation proposal,
depending on progress made towards completing a strategic transaction and
the nature of such a deal. In addition, the Management Board will discuss
at the EGM the previously announced notice of loss pursuant to § 92 par. 1
AktG.
In addition to continuing to pursue strategic opportunities such as
potential combinations with other life sciences companies, Agennix is
continuing to take steps to further conserve cash, including an additional
staff reduction, as well as plans to de-list from the Prime Standard
sub-section of the Frankfurt Stock Exchange and list on the General
Standard of the regulated market.
END OF AD HOC ANNOUNCEMENT
Agennix AG is a publicly listed biopharmaceutical company. The Company's
clinical development programs include oral talactoferrin alfa; a topical
gel form of talactoferrin and RGB-286638, a multi-targeted kinase
inhibitor. Agennix's registered seat is in Heidelberg, Germany. The
Company's site of operation is in Princeton, New Jersey. For additional
information, please visit the Agennix website at www.agennix.com.
This ad hoc announcement contains forward-looking statements, which
express the current beliefs and expectations of the management of Agennix
AG. Such statements are based on current expectations and are subject to
risks and uncertainties, many of which are beyond our control, that could
cause future results, performance or achievements to differ significantly
from those expressed or implied by such forward-looking statements. Actual
results could differ materially depending on a number of factors, and we
caution investors not to place undue reliance on the forward-looking
statements contained in this ad hoc announcement. There can be no guarantee
that the Company will have or be able to obtain additional financial
resources to avoid insolvency or that it will be successful in pursuing a
strategic transaction. Forward-looking statements speak only as of the date
on which they are made and Agennix undertakes no obligation to update these
forward-looking statements, even if new information becomes available in
the future.
Agennix(R) is a trademark of Agennix AG.
For further information, please contact:
Barbara Mueller
Manager, Investor Relations & Corporate Communications
Phone: +49 (0)89 90 40 5464
ir@agennix.com
09.04.2013 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Agennix AG
Im Neuenheimer Feld 515
69120 Heidelberg
Germany
Phone: +49 (0)89 90 405 464
Fax: +49 (0)89 90 405 811
E-mail: ir@agennix.com
Internet: www.agennix.com
ISIN: DE000A1A6XX4
WKN: A1A6XX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Ad Hoc Announcement
According to Sec. 15 WPHG
For Immediate Release
Agennix AG Announces Extraordinary General Meeting
Munich (Germany) and Princeton, NJ, April 9, 2013 - The Management Board
and Supervisory Board of Agennix AG (Frankfurt Stock Exchange: AGX) today
have approved an agenda for an Extraordinary General Meeting (EGM) to be
held on May 22, 2013, including proposals for the liquidation of Agennix AG
and a 20:1 reverse stock split. The Company continues to pursue various
strategic options and will ask shareholders to vote on these two proposals,
among other items. The liquidation of Agennix AG would eliminate the public
entity but still permit potential transactions involving the Company's
clinical assets and its U.S. subsidiaries as part of the process. The
reverse stock split is proposed to reduce the number of outstanding shares
to address the situation under § 92 par. 1 AktG by covering losses and to
permit issuance of shares in connection with a potential strategic
transaction. Management expects to make a recommendation by the date of the
EGM to approve either the reverse stock split or the liquidation proposal,
depending on progress made towards completing a strategic transaction and
the nature of such a deal. In addition, the Management Board will discuss
at the EGM the previously announced notice of loss pursuant to § 92 par. 1
AktG.
In addition to continuing to pursue strategic opportunities such as
potential combinations with other life sciences companies, Agennix is
continuing to take steps to further conserve cash, including an additional
staff reduction, as well as plans to de-list from the Prime Standard
sub-section of the Frankfurt Stock Exchange and list on the General
Standard of the regulated market.
END OF AD HOC ANNOUNCEMENT
Agennix AG is a publicly listed biopharmaceutical company. The Company's
clinical development programs include oral talactoferrin alfa; a topical
gel form of talactoferrin and RGB-286638, a multi-targeted kinase
inhibitor. Agennix's registered seat is in Heidelberg, Germany. The
Company's site of operation is in Princeton, New Jersey. For additional
information, please visit the Agennix website at www.agennix.com.
This ad hoc announcement contains forward-looking statements, which
express the current beliefs and expectations of the management of Agennix
AG. Such statements are based on current expectations and are subject to
risks and uncertainties, many of which are beyond our control, that could
cause future results, performance or achievements to differ significantly
from those expressed or implied by such forward-looking statements. Actual
results could differ materially depending on a number of factors, and we
caution investors not to place undue reliance on the forward-looking
statements contained in this ad hoc announcement. There can be no guarantee
that the Company will have or be able to obtain additional financial
resources to avoid insolvency or that it will be successful in pursuing a
strategic transaction. Forward-looking statements speak only as of the date
on which they are made and Agennix undertakes no obligation to update these
forward-looking statements, even if new information becomes available in
the future.
Agennix(R) is a trademark of Agennix AG.
For further information, please contact:
Barbara Mueller
Manager, Investor Relations & Corporate Communications
Phone: +49 (0)89 90 40 5464
ir@agennix.com
09.04.2013 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Agennix AG
Im Neuenheimer Feld 515
69120 Heidelberg
Germany
Phone: +49 (0)89 90 405 464
Fax: +49 (0)89 90 405 811
E-mail: ir@agennix.com
Internet: www.agennix.com
ISIN: DE000A1A6XX4
WKN: A1A6XX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Aktuelle Themen
Weitere Artikel des Autors
Verfasst von EQS Group AG
URL kopieren
Per E-Mail teilen
Artikel drucken1 im Artikel enthaltener WertIm Artikel enthaltene Werte
Auch bei Lesern beliebt
